



Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
Cyber One, Unit No. 902, Sector 30A,
Plot No - 4 & 6, Vashi,
Navi Mumbai - 400703, India
T: +91 22 2789 2924
F: +91 22 2789 2942

Date: 17th November 2025

To,
The General Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001

Scrip Code: 544292

Subject: Application under Regulation 37 of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 for the proposed Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) under Sections 230 to 232 read with Section 234, Section 52, Section 66 and other applicable provisions of the Indian Companies Act, 2013 and the provisions of Section 210 read with Section 212 and other applicable provisions of the Singapore Companies Act, 1967, amongst Steriscience Specialties Private Limited (“SSPL” or “Transferor Company 1”) and Brooks Steriscience Limited (“BSL” or “Transferee Company 1” or “Transferor Company 2”) and Steriscience Pte. Limited (“Steriscience SG” or “Transferor Company 3”) and Strides Pharma Services Private Limited (“SPSPL” or “Transferor Company 4”) and OneSource Specialty Pharma Limited (“OneSource” or “Transferee Company 2”) and their respective shareholders (the “Scheme” or “Draft Scheme”)

Ref: SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 (SEBI Circular)

This has reference to the captioned application filed by the Company on October 09, 2025, and subsequently hosting of the Draft Scheme related documents on BSE Website on October 24, 2025.

In terms of the SEBI Circular, the Company is required to submit a Complaints Report on the Draft Scheme within 7 days of expiry of 21 days from the date of hosting of the Scheme on the website of BSE

Accordingly, please find enclosed herewith the Complaints Report for the period from October 24, 2025 to November 14, 2025.

As detailed in the Complaints Report, the Company has received “nil” complaints/ comments from the shareholders on the draft Scheme.

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Company Secretary
ICSI Membership No.: A47635

Corporate Office:
 Star 1, Opp IIM Bangalore, Bilekahalli,
 Bannerghatta Road, Bengaluru –
 560076, India
 T: +91 80 6784 0738

Registered Office:
 Cyber One, Unit No. 902, Sector 30A,
 Plot No - 4 & 6, Vashi,
 Navi Mumbai - 400703, India
 T: +91 22 2789 2924
 F: +91 22 2789 2942

Date: November 17, 2025

Complaints Report for the period from October 24, 2025 to November 14, 2025

Part A

Sr. No.	Particulars	Number
1.	Number of complaints received directly	Nil
2.	Number of complaints forwarded by Stock Exchange	Nil
3.	Total Number of complaints/comments received (1+2)	Nil
4.	Number of complaints resolved	-
5.	Number of complaints pending	-

Part B

Sr. No.	Name of complainant	Date of complaint	Status (Resolved/Pending)	Brief Details of the Complaint
1.	-	-	-	-

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
 Company Secretary
 ICSI Membership No.: A47635
 Date: November 17, 2025